Clinical Trials Browser

Approved for marketing × lenvatinib × Clear all

NCT03533361 2018-12-17

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Approved for marketing

Thyroid Neoplasms

NCT02211222 2016-03-16

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Approved for marketing

Thyroid Neoplasms